|
Dear Partners:
 We are excited to share the findings of a new study conducted within the NIDA Clinical Trials Network, which suggests that a buprenorphine/naloxone combination and an extended release naltrexone formulation show similar patient outcomes in the treatment of opioid use disorder (OUD) once the medications are initiated. As hypothesized, it was more difficult for active opioid users to initiate treatment with naltrexone, since using this drug requires complete detoxification.
"The good news is we filled the evidentiary void, and also learned that, for those who were able to initiate treatment, the outcomes were essentially identical, as were adverse events," said John Rotrosen, M.D., the study lead investigator. "This gives patients the freedom to choose a treatment approach that best suits their lifestyle, goals, and wishes."
More on OUD Treatment
Visit the NIDAMED Treatment Information page for other OUD treatment study findings and for resources on opioid and drug addiction treatment for both clinicians and patients.
Share the News!
Please share this message with members, peers, and colleagues and visit NIDAMED for updates on on the rapidly evolving field of opioid treatment. If you would like sample promotional material (e.g., social media messages, graphics, or brief text) to share this information, please contact the NIDAMED coordinator, Michelle Corbin.
With kind regards,
Follow NIDA on Twitter and Facebook.
|
